Get the Stockscreener App
1.65
4.62%
-0.08
Pre-market:
1.65
Inflarx N V stock is traded at $1.65, with a volume of 259.26K.
It is down -4.62% in the last 24 hours and up +63.37% over the past month.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
See More
Previous Close:
$1.73
Open:
$1.75
24h Volume:
259.26K
Relative Volume:
0.65
Market Cap:
$82.65M
Revenue:
-
Net Income/Loss:
$-46.12M
P/E Ratio:
-1.9093
EPS:
-0.8642
Net Cash Flow:
$-41.02M
1W Performance:
+35.25%
1M Performance:
+63.37%
6M Performance:
+3.12%
1Y Performance:
+19.57%
1-Day Range:
$1.62
$1.85
1-Week Range:
$1.29
$1.89
52-Week Range:
$0.8238
$2.815
Inflarx N V Stock (IFRX) Company Profile
Compare IFRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
1.65 | 82.65M | 0 | -46.12M | -41.02M | -0.8642 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-23 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-28-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-06-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-08-20 | Initiated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Apr-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-05-19 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-05-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-05-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Jun-05-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-05-19 | Downgrade | SunTrust | Buy → Hold |
| Jan-29-19 | Initiated | Robert W. Baird | Outperform |
| Dec-10-18 | Initiated | Credit Suisse | Outperform |
| Jul-13-18 | Initiated | BMO Capital Markets | Outperform |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-28-18 | Initiated | SunTrust | Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Inflarx N V Stock (IFRX) Latest News
Geode Capital Management LLC Grows Stake in InflaRx (NASDAQ:IFRX) - Defense World
InflaRx To Reveal Next Month Its Late-Stage Interim Results Of Lead Drug In Painful Ulcer - RTTNews
InflaRx (NASDAQ:IFRX) Earns Overweight Rating from Analysts at Cantor Fitzgerald - Defense World
Cantor Fitzgerald Predicts InflaRx FY2025 Earnings - Defense World
InflaRx (IFRX) Projected to Post Quarterly Earnings on Wednesday - Defense World
What is InflaRx N.V (IFRX) Stock Return on Shareholders’ Capital? - Sete News
Checking in on InflaRx N.V (IFRX) after recent insiders movement - knoxdaily.com
InflaRx N.V (IFRX) Stock: The Story of a 52-Week Stock Range - investchronicle.com
InflaRx N.V (IFRX) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
InflaRx to Report First Quarter 2025 Results on May 7, 2025 - GlobeNewswire
InflaRx, Pioneer in Anti-Inflammatory Therapeutics, Announces Q1 2025 Earnings Date - Stock Titan
Cantor Fitzgerald Initiates Coverage of InflaRx N.V. (IFRX) with Overweight Recommendation - MSN
Cantor Fitzgerald sets $10 target for Inflarx stock, cites catalysts By Investing.com - Investing.com South Africa
Biotech Shares Jump As Institutional Coverage Begins With Positive Outlook - The Globe and Mail
Cantor Fitzgerald sets $10 target for Inflarx stock, cites catalysts - Investing.com
Cantor Fitzgerald Initiates InflaRx at Overweight $10 Price Target - marketscreener.com
InflaRx (IFRX) Projected to Rise with Upcoming Phase 3 Data Rele - GuruFocus
InflaRx Approves Key Resolutions at Annual Shareholder Meeting - MSN
InflaRx launches public offering of shares and warrants - MSN
Commonwealth Equity Services LLC Has $275,000 Stock Holdings in InflaRx (NASDAQ:IFRX) - Defense World
InflaRx N.V. Announces 2025 Annual General Meeting Agenda - TipRanks
Raymond James Financial Inc. Purchases Shares of 638,092 InflaRx (NASDAQ:IFRX) - Defense World
Guggenheim Forecasts Strong Price Appreciation for InflaRx (NASDAQ:IFRX) Stock - Defense World
Guggenheim raises Inflarx stock target to $10, maintains Buy rating By Investing.com - Investing.com Australia
InflaRx price target raised to $10 from $7 at Guggenheim - TipRanks
InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Guggenheim raises Inflarx stock target to $10, maintains Buy rating - Investing.com India
HC Wainwright Reiterates “Buy” Rating for InflaRx (NASDAQ:IFRX) - Defense World
InflaRx N.V. Reports 2024 Results and Key Achievements - TipRanks
InflaRx NV reports results for the quarter ended December 31Earnings Summary - TradingView
InflaRx stock reiterated at Buy at H.C. Wainwright after EU drug approval - MSN
InflaRx reports Q EPS (EUR 0.78) vs (EUR 0.78) last year - TipRanks
InflaRx Reports 2024 Results and Outlines 2025 Milestones - TipRanks
InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones - GlobeNewswire
InflaRx 2024 Earnings Reveal Strong Cash Position and Major EU Drug Win - StockTitan
Short Interest in InflaRx (NASDAQ:IFRX) Grows By 46.2% - Defense World
InflaRx (IFRX) Projected to Post Earnings on Thursday - Defense World
InflaRX Presents Efficacy and Safety Data on Vilobelimab at AAD 2025 - Dermatology Times
InflaRx (NASDAQ:IFRX) Earns Buy Rating from HC Wainwright - Defense World
InflaRx announces presentation of multiple posters on utility of vilobelimab - TipRanks
InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting - GlobeNewswire
Can This Drug Transform Hidradenitis Suppurativa Treatment? New Data Shows 3x Better Results - StockTitan
InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting - GlobeNewswire
Can InflaRx's Vilobelimab Transform Treatment for These Rare Skin Diseases? - StockTitan
InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences - GlobeNewswire
InflaRx N.V. to Release Fourth Quarter 2024 Financial Results and Participate in Key Investor Conferences - Nasdaq
InflaRx Financial Results Coming March 20: What's Next for this Anti-Inflammatory Therapeutics Developer? - StockTitan
Short Interest in InflaRx (NASDAQ:IFRX) Decreases By 13.7% - MarketBeat
InflaRx Concludes $30 Million Public Offering - TipRanks
InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewswire
InflaRx commences offering of ordinary shares and pre-funded warrants - MSN
Inflarx N V Stock (IFRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
3.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):